Thu, 16th May 2013 06:53
May 16 (Reuters) - Hikma Pharmaceuticals Plc raisedits full-year revenue forecast, saying its generic antibioticdoxycycline was generating revenue ahead of its expectations.
The company said it expected group revenue to rise about 13percent in 2013, up from previous forecast of around 10 percent
Hikma reported revenue of $1.11 billion in 2012.
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday:
(Sharecast News) - Citi lifted its price target on Hikma Pharmaceuticals on Tuesday to 2,845p from 2,770p as it said IQVIA April data highlighted "hea...
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:
(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth readi...
Hikma Pharmaceuticals (HIK)